-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

Sponsor: AbbVie, AstraZeneca, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events, Biological Processes, Minimal Residual Disease
Friday, December 8, 2023: 11:00 AM-2:00 PM
Ballroom 20CD (San Diego Convention Center)
Prof. John G. Gribben, MD, DSc, Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
Gribben: Janssen Pharmaceuticals, Inc: Consultancy, Research Funding, Speakers Bureau; Kite, A Gilead Company: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Research Funding; Bristol Myers Squibb: Speakers Bureau; AbbVie: Consultancy, Speakers Bureau; Novartis: Consultancy.
Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical Center , Meghan C. Thompson, MD, Memorial Sloan Kettering Cancer Center and John N. Allan, MD, Weill Cornell Medicine
Lamanna: Oncternal: Research Funding; MingSight: Research Funding; Pharmacyclics: Consultancy; Eli Lilly/Loxo: Research Funding; Adaptive Biotechnologies: Consultancy; Octapharma: Research Funding; Janssen: Consultancy; BeiGene: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; TG Therapeutics: Research Funding; Abbvie: Consultancy, Research Funding. Thompson: Massachusetts Medical Society: Honoraria; Curio Science: Honoraria; Dava Oncology: Honoraria, Other: Travel ; VJHemOnc: Honoraria; Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH): Honoraria; Intellisphere LLC: Honoraria; MJH Life Sciences: Honoraria; Genmab: Research Funding; AstraZeneca: Consultancy, Research Funding; Genentech: Research Funding; Abbvie: Consultancy, Research Funding; Nurix Therapeutics: Other: travel support, Research Funding; Beigene: Consultancy, Research Funding; Loxo Oncology at Lilly: Consultancy; Janssen: Consultancy; Philips Group Oncology Communications: Honoraria. Allan: Lilly: Consultancy; Genentech, Inc.: Consultancy, Research Funding; Janssen: Consultancy, Research Funding, Speakers Bureau; Lava Therapeutics: Consultancy; ADC Therapeutics SA: Consultancy; TG Therapeutics, Inc: Consultancy, Research Funding; Pharmacyclics LLC: Consultancy, Speakers Bureau; Adaptive Biotechnologies: Consultancy; BeiGene: Consultancy, Honoraria, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau; Epizyme: Consultancy; AstraZeneca: Consultancy, Honoraria.
On Demand program will be available here December 13, 2023.

This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.

This activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Choosing well and wisely when deciding on the management of CLL has never been more important. Modern therapeutic platforms based on BTKi and BCL2i have demonstrated efficacy against higher-risk disease, in the relapsed/refractory setting, and as combination or sequential strategies, and newer chemosparing combinations and non-covalent BTKi are poised to overcome challenges in CLL. How will these developments be used going forward, and is long-lasting disease suppression an achievable goal?

Find out by joining an expert panel convened to take on the challenges of CLL and who will share real-world cases to provide guidance on how to implement modern treatment protocols and cover topics such as: choosing between continuous or fixed-duration first-line regimens; BTKi/BCL2i combination platforms; and sequential therapy with non-covalent BTKi options. In partnership with the CLL Society, these important topics will be framed by patient perspectives, including commentary from CLL survivors.